Abstract
Background: Transcatheter aortic valve implantation (TAVI) is an increasingly common treatment of symptomatic severe aortic valve stenosis (AS). Thus, it is reasonable to carefully investigate the impact of individual clinical factors on outcomes after TAVI.
Objectives: We aimed to investigate the impact of the previous cerebro-vascular events (CVEs) on outcomes of patients with severe AS undergoing TAVI.
Methods: A total of 148 consecutive patients scheduled for TAVI were included and stratified as with and without a history of CVEs (stroke or transient ischemic attack). Frailty features were also assessed. The primary endpoint was a 12-month all-cause mortality.
Results: Seventeen (11.5%) patients had a history of CVEs (the CVE group). At 30 days and 12 months, all-cause mortality was higher in the CVE group [30-day: 5 (29.4%) vs. 7 (5.3%); p=0.005; 12-month: 9 (52.9%) vs. 13 (9.9%); p=0.001]. Similarly, at the longest available follow-up, mortality was higher in the CVE group [10 (58.8%) vs. 23 (17.6%); p=0.001]. Similar rates of other complications after TAVI were noted, apart from inhospital acute kidney injury (AKI) grade 3 [3 (17.6%) vs. 5 (3.8%); p=0.049] and blood transfusions [9 (52.9%) vs. 35 (26.7%); p=0.026]. Results of 5MWT and Katz index assessment indicated a greater level of frailty in the CVE group. There were no differences in subsequent events including CVEs, bleeding, myocardial infarction, and new-onset of atrial fibrillation (AF) at 12 months between the groups.
Conclusion: We showed that a history of CVEs in patients with severe AS undergoing TAVI is associated with a higher long-term mortality.
Keywords: Aortic stenosis, elderly, stroke, transcatheter aortic valve replacement, transient ischemic attack.
Current Pharmaceutical Design
Title:Impact of Pre-procedural Cerebrovascular Events on Clinical Outcomes After Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis
Volume: 24 Issue: 5
Author(s): Agata Wiktorowicz, Pawel Kleczynski*, Artur Dziewierz, Tomasz Tokarek, Danuta Sorysz, Maciej Bagienski, Lukasz Rzeszutko and Dariusz Dudek
Affiliation:
- 2nd Department of Cardiology, Jagiellonian University Medical College, Krakow,Poland
Keywords: Aortic stenosis, elderly, stroke, transcatheter aortic valve replacement, transient ischemic attack.
Abstract: Background: Transcatheter aortic valve implantation (TAVI) is an increasingly common treatment of symptomatic severe aortic valve stenosis (AS). Thus, it is reasonable to carefully investigate the impact of individual clinical factors on outcomes after TAVI.
Objectives: We aimed to investigate the impact of the previous cerebro-vascular events (CVEs) on outcomes of patients with severe AS undergoing TAVI.
Methods: A total of 148 consecutive patients scheduled for TAVI were included and stratified as with and without a history of CVEs (stroke or transient ischemic attack). Frailty features were also assessed. The primary endpoint was a 12-month all-cause mortality.
Results: Seventeen (11.5%) patients had a history of CVEs (the CVE group). At 30 days and 12 months, all-cause mortality was higher in the CVE group [30-day: 5 (29.4%) vs. 7 (5.3%); p=0.005; 12-month: 9 (52.9%) vs. 13 (9.9%); p=0.001]. Similarly, at the longest available follow-up, mortality was higher in the CVE group [10 (58.8%) vs. 23 (17.6%); p=0.001]. Similar rates of other complications after TAVI were noted, apart from inhospital acute kidney injury (AKI) grade 3 [3 (17.6%) vs. 5 (3.8%); p=0.049] and blood transfusions [9 (52.9%) vs. 35 (26.7%); p=0.026]. Results of 5MWT and Katz index assessment indicated a greater level of frailty in the CVE group. There were no differences in subsequent events including CVEs, bleeding, myocardial infarction, and new-onset of atrial fibrillation (AF) at 12 months between the groups.
Conclusion: We showed that a history of CVEs in patients with severe AS undergoing TAVI is associated with a higher long-term mortality.
Export Options
About this article
Cite this article as:
Wiktorowicz Agata , Kleczynski Pawel *, Dziewierz Artur , Tokarek Tomasz , Sorysz Danuta , Bagienski Maciej, Rzeszutko Lukasz and Dudek Dariusz , Impact of Pre-procedural Cerebrovascular Events on Clinical Outcomes After Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis, Current Pharmaceutical Design 2018; 24 (5) . https://dx.doi.org/10.2174/1381612824666180219145229
DOI https://dx.doi.org/10.2174/1381612824666180219145229 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cell Behavior at Hypothermia: A Review Article
Current Stem Cell Research & Therapy Total Bakkenolides Protects Neurons Against Cerebral Ischemic Injury Through Inhibition of Nuclear Factor-κB Activation
CNS & Neurological Disorders - Drug Targets Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
Current Vascular Pharmacology Valproic Acid Attenuates Neuronal Loss in the Brain of APP/PS1 Double Transgenic Alzheimer’s Disease Mice Model
Current Alzheimer Research Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer's Disease
Current Topics in Medicinal Chemistry Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure
Current Pharmaceutical Design A Versatile Stability-indicating Liquid Chromatographic Method for the Simultaneous Determination of Atenolol, Hydrochlorothiazide and Chlorthalidone
Current Pharmaceutical Analysis Motion Analysis of the Carotid Artery Wall and Plaque Using B-Mode Ultrasound
Vascular Disease Prevention (Discontinued) Clinical Applications of Non-Antimicrobial Actions of Tetracyclines in Inflammatory Diseases
Current Drug Therapy Metabolic Syndrome and Cardiometabolic Risk Factors
Current Vascular Pharmacology Pharmacologic Modulators of Soluble Guanylate Cyclase/Cyclic Guanosine Monophosphate in the Vascular System - From Bench Top to Bedside
Current Vascular Pharmacology n-Butyl-α-D-fructofuranoside Isolated from Ulmus davidiana Enhances Nrf2 Activity Through Activation of JNK
Current Pharmaceutical Biotechnology Gene Therapy for Neuroprotection and Neurorestoration (Part I)
Current Gene Therapy The Role of Amino Acids in the Modulation of Cardiac Metabolism During Ischemia and Heart Failure
Current Pharmaceutical Design Polymeric Nanoparticles of Aromatase Inhibitors: A Comprehensive Review
Current Pharmaceutical Design Editorial [ The Metabolic Syndrome: Revisiting the Concept, the Diagnosis and the Treatment (Part-I)Guest Editors: John H. McNeill and Vijay Sharma ]
Current Vascular Pharmacology A Mixed Anti-Inflammatory and Pro-Inflammatory Response Associated with a High Dose of Corticosteroids
Current Molecular Medicine Design and Synthesis of Novel 1,3-Dioxane-2-carboxylic Acid Derivatives as PPARα/γ Dual Agonists
Letters in Drug Design & Discovery Dysfunction of Cellular Transporters and Predisposition to Diabetic Nephropathy
Current Diabetes Reviews Cardiac Remodeling and Exercise Training in Hypertension
Current Hypertension Reviews